{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:44:49Z","timestamp":1781354689584,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00737-025-01610-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:54:43Z","timestamp":1752141283000},"page":"1473-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanism of intermittent dosing of fluoxetine in premenstrual dysphoric disorder"],"prefix":"10.1007","volume":"28","author":[{"given":"Tara","family":"Tamton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Matadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-8016","authenticated-orcid":false,"given":"Rif S.","family":"El-Mallakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"1610_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev-clinpsy-050718-095557","volume":"15","author":"A Albert","year":"2019","unstructured":"Albert A, Newhouse P (2019) Estrogen, stress, and depression: cognitive and biological interactions. Annual Rev Clin Psychol 15:399\u2013423. https:\/\/doi.org\/10.1146\/annurev-clinpsy-050718-095557","journal-title":"Annual Rev Clin Psychol"},{"key":"1610_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders 5th edition. American Psychiatric Press, Washington, DC","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"6","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","volume":"43","author":"SE Ball","year":"1997","unstructured":"Ball SE, Ahern D, Scatina J et al (1997) Venlafaxine: in vitro Inhibition of CYP2D6 dependent Imipramine and Desipramine metabolism; comparative studies with selected ssris, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. J Clin Pharmacol 43(6):619\u2013626. https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00591.x","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0306-4530(01)00054-3","volume":"27","author":"C Bethea","year":"2002","unstructured":"Bethea C, Mirkes S, Su A et al (2002) Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinol 27(4):431\u2013445. https:\/\/doi.org\/10.1016\/S0306-4530(01)00054-3","journal-title":"Psychoneuroendocrinol"},{"key":"1610_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737175.2024.2374024","volume":"22","author":"J Blanco","year":"2024","unstructured":"Blanco J, Quimbaya P, Mena M et al (2024) Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder. Expert Rev Neurother 22:1\u201312. https:\/\/doi.org\/10.1080\/14737175.2024.2374024","journal-title":"Expert Rev Neurother"},{"issue":"9102","key":"1610_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s0140-6736(97)04161-5","volume":"351","author":"DW Cameron","year":"1998","unstructured":"Cameron DW, Heath-Chiozzi M, Danner S et al (1998) Randomised placebo-controlled trial of Ritonavir in advanced HIV-1 disease. The advanced HIV disease Ritonavir study group. Lancet 351(9102):543\u2013549. https:\/\/doi.org\/10.1016\/s0140-6736(97)04161-5","journal-title":"Lancet"},{"issue":"2","key":"1610_CR7","doi-asserted-by":"publisher","first-page":"19ac13071","DOI":"10.4088\/JCP.19ac13071","volume":"81","author":"SV Carlini","year":"2020","unstructured":"Carlini SV, Deligiannidis KM (2020) Evidence-based treatment of premenstrual dysphoric disorder: A concise review. J Clin Psychiatry 81(2):19ac13071. https:\/\/doi.org\/10.4088\/JCP.19ac13071","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1610_CR8","first-page":"163","volume":"13","author":"F Celotti","year":"1992","unstructured":"Celotti F, Melcangi RC, Martini L (1992) The 5 alpha-reductase in the brain: molecular aspects and relation to brain function. Front Neuroendocrinol 13(2):163\u2013215","journal-title":"Front Neuroendocrinol"},{"issue":"3","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s0029-7844(02)02166-x","volume":"100","author":"LS Cohen","year":"2002","unstructured":"Cohen LS, Miner C, Brown EW et al (2002) Premenstrual daily Fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Ob Gynecol 100(3):435\u2013444. https:\/\/doi.org\/10.1016\/s0029-7844(02)02166-x","journal-title":"Ob Gynecol"},{"issue":"5","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/cancers14051128","volume":"14","author":"A Davies","year":"2022","unstructured":"Davies A, Cinieri S, Dupoiron D et al (2022) A prospective, real-world, multinational study of Naloxegol for patients with cancer pain diagnosed with opioid-induced constipation-The NACASY study. Cancers (Basel) 14(5):1128. https:\/\/doi.org\/10.3390\/cancers14051128","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","volume":"74","author":"ED Deeks","year":"2014","unstructured":"Deeks ED (2014) Cobicistat: A review of its use as a Pharmacokinetic enhancer of Atazanavir and Darunavir in patients with HIV-1 infection. Drugs 74(2):195\u2013206. https:\/\/doi.org\/10.1007\/s40265-013-0160-x","journal-title":"Drugs"},{"issue":"2","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/pharmaceutics13020148","volume":"13","author":"M Deodhar","year":"2021","unstructured":"Deodhar M, Rihani SBA, Darakjian L et al (2021) Assessing the mechanism of fluoxetine-mediated CYP2D6 Inhibition. Pharmaceutics 13(2):148. https:\/\/doi.org\/10.3390\/pharmaceutics13020148","journal-title":"Pharmaceutics"},{"issue":"1\u20133","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejphar.2007.08.017","volume":"576","author":"JD Deupree","year":"2007","unstructured":"Deupree JD, Montgomery MD, Bylund DB (2007) Pharmacological properties of the active metabolites of the antidepressants Desipramine and Citalopram. Eur J Pharmacol 576(1\u20133):55\u201360. https:\/\/doi.org\/10.1016\/j.ejphar.2007.08.017","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA et al (2021) Selective serotonin reuptake inhibitors and adverse effects: A narrative review. Neurol Int 13(3):387\u2013401. https:\/\/doi.org\/10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"issue":"5","key":"1610_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1176\/appi.ps.53.5.580","volume":"53","author":"RS El-Mallakh","year":"2002","unstructured":"El-Mallakh RS, Karippot A (2002) Use of antidepressants to treat depression in bipolar disorder. Psychiatr Serv 53(5):580\u2013584. https:\/\/doi.org\/10.1176\/appi.ps.53.5.580","journal-title":"Psychiatr Serv"},{"issue":"5","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/jwh.1.1999.8.663","volume":"8","author":"J Endicott","year":"2014","unstructured":"Endicott J, Amsterdam J, Eriksson E et al (2014) Is premenstrual dysphoric disorder a distinct clinical entity? J women\u2019s health. Gender-Based Med 8(5):663\u2013679. https:\/\/doi.org\/10.1089\/jwh.1.1999.8.663","journal-title":"Gender-Based Med"},{"issue":"2","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JCP.0b013e3181678a28","volume":"28","author":"E Eriksson","year":"2008","unstructured":"Eriksson E, Ekman A, Sinclair S et al (2008) Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28(2):195\u2013202. https:\/\/doi.org\/10.1097\/JCP.0b013e3181678a28","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1610_CR18","first-page":"291","volume":"26","author":"M Flores-Ramos","year":"2003","unstructured":"Flores-Ramos M, Ontiveros-Uribe MP, Cortes Sotres J (2003) Comparison between continuous and intermittent treatment with Citalopram for premenstrual dysphoric disorder. Salud Mental 26(3):291\u2013301","journal-title":"Salud Mental"},{"issue":"3","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"CD003415","DOI":"10.1002\/14651858.CD003415.pub4","volume":"2012","author":"O Ford","year":"2012","unstructured":"Ford O, Lethaby A, Roberts H, Mol BW (2012) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012(3):CD003415. https:\/\/doi.org\/10.1002\/14651858.CD003415.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4088\/pcc.v05n0106","volume":"5","author":"EW Freeman","year":"2003","unstructured":"Freeman EW, Sondheimer SJ (2003) Premenstrual dysphoric disorder: recognition and treatment. Prim. Care Compan. J Clin Psychiatry 5(1):30\u201339. https:\/\/doi.org\/10.4088\/pcc.v05n0106","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00004714-199406000-00005","volume":"14","author":"EW Freeman","year":"1994","unstructured":"Freeman EW, Rickels K, Sondheimer SJ et al (1994) Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol 14(3):180\u2013186","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1610_CR25","first-page":"303","volume":"33","author":"EW Freeman","year":"1997","unstructured":"Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33(2):303\u2013309","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/archpsyc.56.10.932","volume":"56","author":"EW Freeman","year":"1999","unstructured":"Freeman EW, Rickels K, Sondheimer SJ et al (1999) Differential response to antidepressants in women with premenstrual syndrome\/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56(10):932\u2013939. https:\/\/doi.org\/10.1001\/archpsyc.56.10.932","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/15246090260137635","volume":"11","author":"EW Freeman","year":"2002","unstructured":"Freeman EW, Jabara S, Sondheimer SJ et al (2002) Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Women\u2019s Health Gender-Based Med 11(5):459\u2013464. https:\/\/doi.org\/10.1089\/15246090260137635","journal-title":"J Women\u2019s Health Gender-Based Med"},{"issue":"2","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.161.2.343","volume":"161","author":"EW Freeman","year":"2004","unstructured":"Freeman EW, Rickels K, Sondheimer SJ et al (2004) Continuous or intermittent dosing with Sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161(2):343\u2013351. https:\/\/doi.org\/10.1176\/appi.ajp.161.2.343","journal-title":"Am J Psychiatry"},{"issue":"24","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.1111\/bph.12891","volume":"171","author":"JP Fry","year":"2014","unstructured":"Fry JP, Li KY, Devall AJ et al (2014) Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase. Br J Pharmacol 171(24):5870\u20135880. https:\/\/doi.org\/10.1111\/bph.12891","journal-title":"Br J Pharmacol"},{"key":"1610_CR27","doi-asserted-by":"publisher","unstructured":"Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED (2014) 5-HT1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacol (Berl) 231(4):623\u2013636. https:\/\/doi.org\/10.1007\/s00213-013-3389-x. Erratum in: Psychopharmacol (Berl) 231(4):637, 2014","DOI":"10.1007\/s00213-013-3389-x"},{"issue":"10","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/medicina55100668","volume":"55","author":"G Gava","year":"2019","unstructured":"Gava G, Orsili I, Alvisi S, I. et al (2019) Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina 55(10):668. https:\/\/doi.org\/10.3390\/medicina55100668","journal-title":"Medicina"},{"issue":"1","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/S003329170800322X","volume":"39","author":"S Gehlert","year":"2009","unstructured":"Gehlert S, Song IH, Chang CH et al (2009) The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med 39(1):129\u2013136. https:\/\/doi.org\/10.1017\/S003329170800322X","journal-title":"Psychol Med"},{"issue":"8","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.pnpbp.2008.07.016","volume":"32","author":"X Gonda","year":"2008","unstructured":"Gonda X, Telek T, Juh\u00e1sz G et al (2008) Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32(8):1782\u20131788. https:\/\/doi.org\/10.1016\/j.pnpbp.2008.07.016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"1610_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1124\/dmd.109.026716","volume":"37","author":"SW Grimm","year":"2009","unstructured":"Grimm SW, Einolf HJ, Hall SD et al (2009) The conduct of in vitro studies to address time-dependent Inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37(7):1355\u20131370. https:\/\/doi.org\/10.1124\/dmd.109.026716","journal-title":"Drug Metab Dispos"},{"key":"1610_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2165\/00023210-200115100-00005","volume":"15","author":"U Halbreich","year":"2001","unstructured":"Halbreich U, Kahn LS (2001) Role of Estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15:797\u2013817. https:\/\/doi.org\/10.2165\/00023210-200115100-00005","journal-title":"CNS Drugs"},{"key":"1610_CR33","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.ynstr.2020.100213","volume":"12","author":"L Hantsoo","year":"2020","unstructured":"Hantsoo L, Epperson CN (2020) Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress 12:100213. https:\/\/doi.org\/10.1016\/j.ynstr.2020.100213","journal-title":"Neurobiol Stress"},{"issue":"1","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/09540121.2015.1069787","volume":"28","author":"NA Hessol","year":"2016","unstructured":"Hessol NA, Holman S, Minkoff H et al (2016) Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV. AIDS Care 28(1):11\u201321. https:\/\/doi.org\/10.1080\/09540121.2015.1069787","journal-title":"AIDS Care"},{"issue":"8","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/ijms18081713","volume":"18","author":"L-H Hsu","year":"2017","unstructured":"Hsu L-H, Chu N-M, Kao S-H (2017) Estrogen, Estrogen receptor and lung cancer. Int J Mol Sci 18(8):1713. https:\/\/doi.org\/10.3390\/ijms18081713","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1610_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","volume":"30","author":"R Huddart","year":"2020","unstructured":"Huddart R, Hicks JK, Ramsey LB et al (2020) PharmGKB summary: Sertraline pathway, pharmacokinetics. Pharmacogenet Genomics 30(2):26\u201333. https:\/\/doi.org\/10.1097\/FPC.0000000000000392","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"1610_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.572905","volume":"43","author":"MW Hull","year":"2011","unstructured":"Hull MW, Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43(5):375\u2013388. https:\/\/doi.org\/10.3109\/07853890.2011.572905","journal-title":"Ann Med"},{"key":"1610_CR38","first-page":"784","volume-title":"Textbook of women\u2019s reproductive mental health","year":"2022","unstructured":"Hunter LA, Catapano LA, Nagle-Yang SM et al (eds) (2022) Textbook of women\u2019s reproductive mental health. American Psychiatric, Washington, DC., p 784"},{"issue":"8","key":"1610_CR39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.biopsych.2006.12.019","volume":"62","author":"L Huo","year":"2007","unstructured":"Huo L, Straub RE, Roca C et al (2007) Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the Estrogen receptor alpha gene. Biol Psychiatry 62(8):925\u2013933. https:\/\/doi.org\/10.1016\/j.biopsych.2006.12.019","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1610_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/ppc.12219x","volume":"54","author":"J Hussein Shehadeh","year":"2018","unstructured":"Hussein Shehadeh J, Hamdan-Mansour AM (2018) Prevalence and association of premenstrual syndrome and premenstrual dysphoric disorder with academic performance among female university students. Perspect Psychiat Care 54(2):176\u2013184. https:\/\/doi.org\/10.1111\/ppc.12219x","journal-title":"Perspect Psychiat Care"},{"issue":"14","key":"1610_CR41","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","volume":"29","author":"C Klinge","year":"2001","unstructured":"Klinge C (2001) Estrogen receptor interaction with Estrogen response elements. Nucleic Acids Res 29(14):2905\u20132919. https:\/\/doi.org\/10.1093\/nar\/29.14.2905","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1610_CR42","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/01.jcp.0000095343.32154.1d","volume":"23","author":"M Kotlyar","year":"2003","unstructured":"Kotlyar M, Brewer ER, Golding M et al (2003) Nefazodone inhibits Methylprednisolone disposition and enhances its adrenal-suppressant effect. J Clin Psychopharmacol 23(6):652\u2013656. https:\/\/doi.org\/10.1097\/01.jcp.0000095343.32154.1d","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1610_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.npp.1301216","volume":"32","author":"M Land\u00e9n","year":"2007","unstructured":"Land\u00e9n M, Nissbrandt H, Allgulander C et al (2007) Placebo-controlled trial comparing intermittent and continuous Paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacol 32(1):153\u2013161. https:\/\/doi.org\/10.1038\/sj.npp.1301216","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"1610_CR44","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/pme.12097","volume":"14","author":"TM Leucker","year":"2013","unstructured":"Leucker TM, Singh S, Moffett BK (2013) Fluoxetine Inhibition of CYP3A4 potentiating adrenal suppression and peptic ulcer disease from intra-articular triamcinolone injections. Pain Med 14(6):952\u2013953. https:\/\/doi.org\/10.1111\/pme.12097","journal-title":"Pain Med"},{"issue":"17","key":"1610_CR45","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","volume":"23","author":"NHC Loos","year":"2022","unstructured":"Loos NHC, Beijnen JH, Schinkel AH (2022) The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int J Mol Sci 23(17):9866. https:\/\/doi.org\/10.3390\/ijms23179866","journal-title":"Int J Mol Sci"},{"key":"1610_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.psyneuen.2016.11.033","volume":"76","author":"C Lundin","year":"2017","unstructured":"Lundin C, Danielsson KG, Bixo M, et aI (2017) Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinol 76:135\u2013143. https:\/\/doi.org\/10.1016\/j.psyneuen.2016.11.033","journal-title":"Psychoneuroendocrinol"},{"issue":"12","key":"1610_CR48","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1124\/dmd.113.052639","volume":"41","author":"JD Lutz","year":"2013","unstructured":"Lutz JD, VandenBrink BM, Babu KN et al (2013) Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metab Disp: Biol Fate Chem 41(12):2056\u20132065. https:\/\/doi.org\/10.1124\/dmd.113.052639","journal-title":"Drug Metab Disp: Biol Fate Chem"},{"key":"1610_CR51","doi-asserted-by":"publisher","first-page":"106360","DOI":"10.1016\/j.psyneuen.2023.106360","volume":"157","author":"MCMF Maranho","year":"2023","unstructured":"Maranho MCMF, Guapo VG, de Rezende MG et al (2023) Low doses of Fluoxetine for the treatment of emotional premenstrual syndrome: a randomized double-blind, placebo-controlled, pilot study. Psychoneuroendocrinol 157:106360. https:\/\/doi.org\/10.1016\/j.psyneuen.2023.106360","journal-title":"Psychoneuroendocrinol"},{"issue":"10","key":"1610_CR49","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0026-895X(24)12048-2","volume":"28","author":"JM Margolis","year":"2000","unstructured":"Margolis JM, O\u2019Donnell JP, Mankowski DC et al (2000) I-, (S)-, and racemic Fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Disp: Biol Fate Chem 28(10):1187\u20131191","journal-title":"Drug Metab Disp: Biol Fate Chem"},{"issue":"6","key":"1610_CR50","doi-asserted-by":"publisher","first-page":"CD001396","DOI":"10.1002\/14651858.CD001396.pub3","volume":"2013","author":"J Marjoribanks","year":"2013","unstructured":"Marjoribanks J, Brown J, O\u2019Brien PM et al (2013) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Systemat Rev 2013(6):CD001396. https:\/\/doi.org\/10.1002\/14651858.CD001396.pub3","journal-title":"Cochrane Database Systemat Rev"},{"issue":"4","key":"1610_CR52","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/npp.2015.246","volume":"41","author":"PE Martinez","year":"2016","unstructured":"Martinez PE, Rubinow DR, Nieman LK et al (2016) 5\u03b1-reductase Inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacol 41(4):1093\u20131102. https:\/\/doi.org\/10.1038\/npp.2015.246","journal-title":"Neuropsychopharmacol"},{"issue":"8","key":"1610_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/bdd.1857","volume":"34","author":"Y Masubuchi","year":"2014","unstructured":"Masubuchi Y, Kawaguchi Y (2014) Time-dependent Inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor. Biopharm Drug Dispos 34(8):423\u2013430. https:\/\/doi.org\/10.1002\/bdd.1857","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"1610_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s0149-2918(02)85043-3","volume":"24","author":"C Miner","year":"2002","unstructured":"Miner C, Brown E, McCray S et al (2002) Weekly luteal-phase dosing with enteric-coated Fluoxetine 90\u00a0mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Th 24(3):417\u2013433. https:\/\/doi.org\/10.1016\/s0149-2918(02)85043-3","journal-title":"Clin Th"},{"issue":"2","key":"1610_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00228-004-0877-2","volume":"61","author":"E Molden","year":"2005","unstructured":"Molden E, Garcia BH, Braathen P, Eggen AE (2005) Co-prescription of cytochrome P450 2D6\/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 61(2):119\u2013125. https:\/\/doi.org\/10.1007\/s00228-004-0877-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"2\u20133","key":"1610_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00510547","volume":"290","author":"A Nagy","year":"1975","unstructured":"Nagy A, Johansson R (1975) Plasma levels of Imipramine and Desipramine in man after different routes of administration. Naunyn Schmiedebergs Arch Pharmacol 290(2\u20133):145\u2013160. https:\/\/doi.org\/10.1007\/BF00510547","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"1610_CR57","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1176\/appi.ajp.157.9.1423","volume":"157","author":"AA Nierenberg","year":"2000","unstructured":"Nierenberg AA, Farabaugh AH, Alpert JE, e al (2000) Timing of onset of antidepressant response with Fluoxetine treatment. Am J Psychiatry 157(9):1423\u20131428. https:\/\/doi.org\/10.1176\/appi.ajp.157.9.1423","journal-title":"Am J Psychiatry"},{"key":"1610_CR58","doi-asserted-by":"publisher","first-page":"14869","DOI":"10.1155\/IDOG\/2006\/14869","volume":"2006","author":"PN Patel","year":"2006","unstructured":"Patel PN, Grimes RM (2006) Symptom exacerbation and adherence to antiretroviral therapy during the menstrual cycle: A pilot study. Infect Dis Obstet Gynecol 2006:14869. https:\/\/doi.org\/10.1155\/IDOG\/2006\/14869","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"9","key":"1610_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1046\/j.1365-2826.2000.00549.x","volume":"12","author":"K-YF Pau","year":"2000","unstructured":"Pau K-YF, Hess DL, Kohama S et al (2000) Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized Rhesus macaques. J Neuroendocrinol 12(9):899\u2013909. https:\/\/doi.org\/10.1046\/j.1365-2826.2000.00549.x","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"1610_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1139\/jpn.0828","volume":"33","author":"T Pearlstein","year":"2008","unstructured":"Pearlstein T, Steiner M (2008) Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 33(4):291\u2013301","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"1610_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4088\/pcc.v07n0203","volume":"7","author":"TB Pearlstein","year":"2005","unstructured":"Pearlstein TB, Bellew KM, Endicott J et al (2005) Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 7(2):53\u201360. https:\/\/doi.org\/10.4088\/pcc.v07n0203","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"1","key":"1610_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-014-0018-5","volume":"3","author":"EP Pioro","year":"2014","unstructured":"Pioro EP (2014) Review of dextromethorphan 20\u00a0mg\/quinidine 10\u00a0mg (NUEDEXTA\u00ae) for pseudobulbar affect. Neurol Ther 3(1):15\u201328. https:\/\/doi.org\/10.1007\/s40120-014-0018-5","journal-title":"Neurol Ther"},{"issue":"4","key":"1610_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","volume":"46","author":"N Rao","year":"2007","unstructured":"Rao N (2007) The clinical pharmacokinetics of Escitalopram. Clin Pharmacokinet 46(4):281\u2013290. https:\/\/doi.org\/10.2165\/00003088-200746040-00002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1610_CR63","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/whe.13.62","volume":"9","author":"A Rapkin","year":"2013","unstructured":"Rapkin A, Lewis E (2013) Treatment of premenstrual dysphoric disorder. Women\u2019s Health 9(6):537\u2013556. https:\/\/doi.org\/10.2217\/whe.13.62","journal-title":"Women\u2019s Health"},{"issue":"1","key":"1610_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","volume":"174","author":"RN Rozner","year":"2019","unstructured":"Rozner RN, Freites-Martinez A, Shapiro J et al (2019) Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat 174(1):15\u201326. https:\/\/doi.org\/10.1007\/s10549-018-4996-3","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1610_CR66","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/clpt.2014.50","volume":"95","author":"JE Sager","year":"2014","unstructured":"Sager JE, Lutz JD, Foti RS et al (2014) Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 95(6):653\u2013662. https:\/\/doi.org\/10.1038\/clpt.2014.50","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1610_CR67","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1037\/bul0000102","volume":"143","author":"RH Salk","year":"2017","unstructured":"Salk RH, Hyde JS, Abramson LY (2017) Gender differences in depression in representative National samples: Meta-analyses of diagnoses and symptoms. Psychol Bull 143(8):783\u2013822. https:\/\/doi.org\/10.1037\/bul0000102","journal-title":"Psychol Bull"},{"issue":"4","key":"1610_CR69","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","volume":"29","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Reines EH, Montgomery SA (2014) A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 29(4):185\u2013196. https:\/\/doi.org\/10.1097\/YIC.0000000000000023","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"1610_CR68","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/a:1006986824213","volume":"19","author":"C S\u00e1nchez","year":"1999","unstructured":"S\u00e1nchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19(4):467\u2013489. https:\/\/doi.org\/10.1023\/a:1006986824213","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"1610_CR71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1749-6632.2009.04982.x","volume":"1179","author":"PJ Schmidt","year":"2009","unstructured":"Schmidt PJ, Rubinow DR (2009) Sex hormones and mood in the perimenopause. Ann New York Acad Sci 1179(1):70\u201385. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04982.x","journal-title":"Ann New York Acad Sci"},{"issue":"4","key":"1610_CR70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJM199801223380401","volume":"338","author":"PJ Schmidt","year":"1998","unstructured":"Schmidt PJ, Nieman LK, Danaceau MA et al (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338(4):209\u2013216. https:\/\/doi.org\/10.1056\/NEJM199801223380401","journal-title":"N Engl J Med"},{"issue":"5","key":"1610_CR72","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/AOG.0b013e31816fd73b","volume":"111","author":"NR Shah","year":"2008","unstructured":"Shah NR, Jones JB, Aperi J et al (2008) Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Ob Gynecol 111(5):1175\u20131182. https:\/\/doi.org\/10.1097\/AOG.0b013e31816fd73b","journal-title":"Ob Gynecol"},{"key":"1610_CR73","volume-title":"StatPearls [Internet]","author":"AJ Sohel","year":"2024","unstructured":"Sohel AJ, Shutter MC, Patel P et al (2024) Fluoxetine. 2024 Feb 28. StatPearls [Internet]. StatPearls Publishing, Treasure Island, Florida"},{"issue":"7","key":"1610_CR74","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/s0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V\u2019 (2008) Clinically relevant Pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206\u20131227. https:\/\/doi.org\/10.1016\/s0149-2918(08)80047-1","journal-title":"Clin Ther"},{"issue":"4","key":"1610_CR75","first-page":"771","volume":"33","author":"M Steiner","year":"1997","unstructured":"Steiner M, Korzekwa M, Lamont J et al (1997) Intermittent Fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 33(4):771\u2013774","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"1610_CR76","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1471-0528.2001.00120.x","volume":"108","author":"M Steiner","year":"2001","unstructured":"Steiner M, Romano SJ, Babcock S et al (2001) The efficacy of Fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG: Int J Ob Gynaecol 108(5):462\u2013468. https:\/\/doi.org\/10.1111\/j.1471-0528.2001.00120.x","journal-title":"BJOG: Int J Ob Gynaecol"},{"key":"1610_CR77","doi-asserted-by":"publisher","unstructured":"Steiner M, Ravindran AV, LeMelledo JM, et al (2008) Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry 69(6):991\u2013998. https:\/\/doi.org\/10.4088\/jcp.v69n0616","DOI":"10.4088\/jcp.v69n0616"},{"key":"1610_CR78","doi-asserted-by":"publisher","unstructured":"Sundstr\u00f6m-Poromaa I, Comasco E, Sumner R, Luders E (2020) Progesterone\u2013 Friend or foe? Frontiers in Neuroendocrinol 2020;59:100856. https:\/\/doi.org\/10.1016\/j.yfrne.2020.100856","DOI":"10.1016\/j.yfrne.2020.100856"},{"key":"1610_CR79","volume-title":"StatPearls [Internet]","author":"DK Thiyagarajan","year":"2022","unstructured":"Thiyagarajan DK, Basit H, Jeanmonod R (2022) Physiology, menstrual cycle. StatPearls [Internet]. StatPearls Publishing, Treasure Island, Florida"},{"issue":"2","key":"1610_CR80","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1677\/jme.1.01907","volume":"36","author":"JM Torres","year":"2006","unstructured":"Torres JM, Ortega E (2006) Steroid 5 alpha-reductase isozymes in the adult female rat brain: central role of dihydrotestosterone. J Mol Endocrinol 36(2):239\u2013245. https:\/\/doi.org\/10.1677\/jme.1.01907","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"1610_CR81","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2125.2011.03988.x","volume":"72","author":"J Troost","year":"2011","unstructured":"Troost J, Tatami S, Tsuda Y et al (2011) Effects of strong CYP2D6 and 3A4 inhibitors, Paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of Tamsulosin. Br J Clin Pharmacol 72(2):247\u2013256. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03988.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1610_CR82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2004.10.007","volume":"227","author":"Y Tsuchiya","year":"2005","unstructured":"Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227(2):115\u2013124. https:\/\/doi.org\/10.1016\/j.canlet.2004.10.007","journal-title":"Cancer Lett"},{"issue":"2","key":"1610_CR83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.physbeh.2009.09.017","volume":"9","author":"A Walf","year":"2010","unstructured":"Walf A, Frye C (2010) Estradiol reduces anxiety- and depression-like behavior of aged female mice. Physiol Behav 9(2):169\u2013174. https:\/\/doi.org\/10.1016\/j.physbeh.2009.09.017","journal-title":"Physiol Behav"},{"issue":"5","key":"1610_CR84","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/00004714-199810000-00007","volume":"18","author":"I Wikander","year":"1998","unstructured":"Wikander I, Sundblad C, Andersch B et al (1998) Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 18(5):390\u2013398. https:\/\/doi.org\/10.1097\/00004714-199810000-00007","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1610_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1017\/S2045796016001220","volume":"27","author":"L Wilson","year":"2018","unstructured":"Wilson L, Pandeya N, Byles J et al (2018) Hysterectomy and incidence of depressive symptoms in midlife women: the Australian longitudinal study on women\u2019s health. Epidemiol Psychiat Sci 27(4):381\u2013392. https:\/\/doi.org\/10.1017\/S2045796016001220","journal-title":"Epidemiol Psychiat Sci"},{"issue":"5","key":"1610_CR86","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0024-3205(95)00209-o","volume":"57","author":"DT Wong","year":"1995","unstructured":"Wong DT, Bymaster FP, Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 57(5):411\u2013441. https:\/\/doi.org\/10.1016\/0024-3205(95)00209-o","journal-title":"Life Sci"},{"issue":"1","key":"1610_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1440-1819.2007.01785.x","volume":"62","author":"KY Wu","year":"2008","unstructured":"Wu KY, Liu CY, Hsiao MC (2008) Six-month Paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols. Psychiatry Clin Neurosci 62(1):109\u2013114. https:\/\/doi.org\/10.1111\/j.1440-1819.2007.01785.x","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"1610_CR93","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/ml1000257","volume":"1","author":"L Xu","year":"2010","unstructured":"Xu L, Liu H, Murray BP et al (2010) Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 1(5):209\u2013213. https:\/\/doi.org\/10.1021\/ml1000257","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"1610_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/rmb2.12006","volume":"16","author":"P Ya\u015far","year":"2017","unstructured":"Ya\u015far P, Ayaz G, User SD et al (2017) Molecular mechanism of estrogen\u2013estrogen receptor signaling. Reprod Med Biol 16(1):4\u201320. https:\/\/doi.org\/10.1002\/rmb2.12006","journal-title":"Reprod Med Biol"},{"issue":"22","key":"1610_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ijerph16224352","volume":"16","author":"J-Y Yen","year":"2019","unstructured":"Yen J-Y, Lin H-C, Lin P-C et al (2019) Early- and late-luteal-phase Estrogen and progesterone levels of women with premenstrual dysphoric disorder. Int J Environ Res Pub Health 16(22):43\u201352. https:\/\/doi.org\/10.3390\/ijerph16224352","journal-title":"Int J Environ Res Pub Health"},{"issue":"3","key":"1610_CR90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jad.2004.10.006","volume":"85","author":"KA Yonkers","year":"2005","unstructured":"Yonkers KA, Pearlstein, Fayyad R et al (2005) Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 85(3):317\u2013321. https:\/\/doi.org\/10.1016\/j.jad.2004.10.006","journal-title":"J Affect Disord"},{"issue":"12","key":"1610_CR91","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archpsyc.57.12.1157","volume":"57","author":"EA Young","year":"2000","unstructured":"Young EA, Midgley AR, Carlson NE et al (2000) Alteration in the hypothalamic\u2013pituitary\u2013ovarian axis in depressed women. Arch Gen Psychiatry 57(12):1157\u20131162. https:\/\/doi.org\/10.1001\/archpsyc.57.12.1157","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"1610_CR92","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1210\/en.2004-1248","volume":"146","author":"AM Yu","year":"2005","unstructured":"Yu AM, Fukamachi K, Krausz KW et al (2005) Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinol 146(7):2911\u20132919. https:\/\/doi.org\/10.1210\/en.2004-1248","journal-title":"Endocrinol"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-025-01610-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:03:59Z","timestamp":1765811039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-025-01610-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s00737-025-01610-0","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. El-Mallakh is a speaker for Axsome, Intracellular, Lundbeck, Otsuka, and Vanda. None of the other authors have any conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}